Saliva Test Fast Tracks Heart Attack Diagnosis
|
By LabMedica International staff writers Posted on 07 Sep 2020 |

Image: A test tube contains saliva that can be tested for the heart attack biomarker cardiac troponin (Photo courtesy of karenfoleyphoto).
Heart attacks need urgent diagnosis, followed by treatment to restore blood flow to blocked arteries. Diagnosis is based on symptoms (such as chest pain), an electrocardiogram (ECG) and a blood test for cardiac troponin, a protein released into the blood when the heart muscle is injured.
A saliva test could fast track heart attack diagnosis, according to a preliminary study. The innovative technique requires patients to spit into a tube and provides results in 10 minutes, compared to at least one hour for the standard blood test and saliva collection is a non-invasive.
Medical scientists at the Soroka University Medical Centre (Be’er Sheva, Israel) examined if cardiac troponin could be detected in the saliva of patients with heart muscle injury. Saliva samples underwent a unique processing procedure to remove highly abundant proteins. The processing procedure is called Saliva High Abundant Proteins Effective Depletion (SHAPED). A total of 32 patients with heart muscle injury (i.e. they had a positive cardiac troponin blood test) and 13 healthy volunteers were requested to provide saliva samples by spitting into a collecting tube. Then, half of each sample was processed, and the other half remained in its natural state. They then tested the processed and unprocessed saliva samples for cardiac troponin.
The investigators compared the results from the saliva samples (processed and unprocessed) with the blood samples. There was strong agreement between the blood findings and the processed saliva, but not saliva in its natural state. Most of the processed saliva samples tested were positive for troponin, compared to just 6% of the unprocessed saliva. Of the 25 patients with myocardial injury whose samples had advanced processing, 21 were confirmed positive for MI by both methods (sensitivity, 84.0%). Among healthy participants, no cardiac troponin was detected in the processed and unprocessed saliva samples.
Roi Westreich, MD, A Cardiologist and lead author of the study, said, “Since no test has been developed for use on saliva, we had to use commercially available tests intended for whole blood, plasma, or serum, and adjust them for saliva examination. This early work shows the presence of cardiac troponin in the saliva of patients with myocardial injury. Further studies are needed to determine how long troponin stays in the saliva after a heart attack. In addition, we need to know how many patients would erroneously be diagnosed with heart attack and how many cases would be missed.” The study was presented at the digital European Society of Cardiology 2020 congress held August 29 to September 1, 2020 via Sophia Antipolis, France.
Related Links:
Soroka University Medical Centre
A saliva test could fast track heart attack diagnosis, according to a preliminary study. The innovative technique requires patients to spit into a tube and provides results in 10 minutes, compared to at least one hour for the standard blood test and saliva collection is a non-invasive.
Medical scientists at the Soroka University Medical Centre (Be’er Sheva, Israel) examined if cardiac troponin could be detected in the saliva of patients with heart muscle injury. Saliva samples underwent a unique processing procedure to remove highly abundant proteins. The processing procedure is called Saliva High Abundant Proteins Effective Depletion (SHAPED). A total of 32 patients with heart muscle injury (i.e. they had a positive cardiac troponin blood test) and 13 healthy volunteers were requested to provide saliva samples by spitting into a collecting tube. Then, half of each sample was processed, and the other half remained in its natural state. They then tested the processed and unprocessed saliva samples for cardiac troponin.
The investigators compared the results from the saliva samples (processed and unprocessed) with the blood samples. There was strong agreement between the blood findings and the processed saliva, but not saliva in its natural state. Most of the processed saliva samples tested were positive for troponin, compared to just 6% of the unprocessed saliva. Of the 25 patients with myocardial injury whose samples had advanced processing, 21 were confirmed positive for MI by both methods (sensitivity, 84.0%). Among healthy participants, no cardiac troponin was detected in the processed and unprocessed saliva samples.
Roi Westreich, MD, A Cardiologist and lead author of the study, said, “Since no test has been developed for use on saliva, we had to use commercially available tests intended for whole blood, plasma, or serum, and adjust them for saliva examination. This early work shows the presence of cardiac troponin in the saliva of patients with myocardial injury. Further studies are needed to determine how long troponin stays in the saliva after a heart attack. In addition, we need to know how many patients would erroneously be diagnosed with heart attack and how many cases would be missed.” The study was presented at the digital European Society of Cardiology 2020 congress held August 29 to September 1, 2020 via Sophia Antipolis, France.
Related Links:
Soroka University Medical Centre
Latest Pathology News
- FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
- New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
- AI System Analyzes Routine Pathology Slides to Predict Cancer Outcomes
- New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease
- Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
- Interpretable AI Reveals Hidden Cellular Features from Microscopy Images
- Tumor Immune Structure Predicts Response to Immunotherapy in Melanoma
- Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides
- AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer
- AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
- Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
- AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
- Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates
- Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
- AI Improves Completeness of Complex Cancer Pathology Reports
- AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
Inflammatory breast cancer is among the most aggressive forms of breast malignancy and remains challenging to diagnose and monitor. Obtaining tumor tissue can be difficult, and standard genome and RNA... Read more
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








